(Q24244091)

secondary hyperparathyroidism

inferred from title

1 reference

3

0 references

Jonathan Craig

5

Jonathan C Craig

0 references

Allison Tong

2

Allison Tong

0 references

Giovanni Strippoli

1

Giovanni FM Strippoli

0 references

Grahame Elder

4

Cochrane Database of Systematic Reviews

Grahame J Elder

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Hyperphosphataemia in renal failure: causes, consequences and current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Bias in location and selection of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Osteoporosis and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Calcimimetic agents: review and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Calcimimetics in action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021

Publication bias: the case for an international registry of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006254

7 January 2021